Merrimack Pharmaceuticals, Inc.: Series F $60M

Posted in I - Series F, Q - 2Q08, R - NORTH EAST, X - Autoimmune, X - Oncology

Merrimack Pharmaceuticals (Cambridge, MA) development-stage biotechnology company focused on novel treatments for autoimmune disease and cancer, closed a $60M Series F financing. Participants include Credit Suisse First Boston, Next Fund, Crocker Ventures, HNI Holdings, Noonday Asset Management, TPG-Axon Capital, and WT Investment Advisors Fund.

Itero Biopharmaceuticals, Inc.: Series A $21M

Posted in I - Series A, Q - 2Q08, R - WEST, X - Biosimilars, X - Generics

Itero Biopharmaceuticals (San Mateo, CA) focused on novel and follow-on protein and antibody therapeutics, closed a $21M Series A financing. Participants include SV Life Sciences, Panorama Capital and VenturEast.

Cameron Health, Inc.: Series E $51.5M

Posted in I - Series E, Q - 2Q08, R - WEST, X - Device (Cardiology)

Cameron Health (San Clemente, CA) maker of implantable devices for treatment of cardiac disorders, closed a $51.5M Series E funding. Participants included PTV Sciences, Boston Scientific, Delphi Ventures, Sorrento Ventures, Three Arch Partners and Versant Ventures.

Immune Design, Inc.: Series A $18M

Posted in I - Series A, Q - 2Q08, R - NORTH WEST, X - Adjuvant, X - Immunology, X - Vaccines

Immune Design (Seattle, WA) vaccine developer focused on regulating immune responses by targeting dendritic cell biology with combinations of proprietary vectors and adjuvants, closed a $18M Series A financing. Participants include Alta Partners, The Column Group and Versant Ventures.

Tolera Therapeutics, Inc. Series A $8M

Posted in I - Series B, Q - 2Q08, R - MID WEST, X - Immunology, X - Oncology, X - Rheumatology, X - Transplant

Tolera Therapeutics (Cleveland, OH) focused on immunotherapeutics for transplantation, oncology and autoimmune disease, closed an $8M Series A financing. Participants include Triathlon Medical Ventures, Southwest Michigan First Life Science Fund and Hopen Therapeutics.

Advanced ICU Care, Inc.: Series B $5M

Posted in I - Series B, Q - 2Q08, R - MID WEST, X - TeleMedicine

Advanced ICU Care (St. Louis, MO) early-stage company focused on telemedicine services, closed a $5M Series B financing. Participants include Versant Ventures.

Isconova, AB: Series A $5M

Posted in I - Series A, Q - 2Q08, R - INTERNATIONAL, X - Adjuvant, X - Immunology, X - Vaccines

Isconova (Sweden) developer of antigen delivery system and adjuvant platform, closed a $5M Series A financing. Participants include Innovations Kapital.

Reily Genomics, Inc: Series B $15M

Posted in I - Series B, Q - 2Q08, R - WEST, X - Device (Diagnostic), X - Rheumatology

Reily Genomics (Palo Alto, CA) early-stage company focused on developing diagnostic tools to effectively manage patients with autoimmune and inflammatory diseases, closed a $15M Series B financing. Participants include Kleiner Perkins Caufield & Byers and Mohr Davidow Ventures.

NanoMR, Inc.: Series A $5.5M

Posted in I - Series A, Q - 2Q08, R - SOUTH WEST, X - Device (Diagnostic)

NanoMR (Albuquerque, NM) early-stage blood diagnostics device startup focused on real time, ultrasensitive detection of samples, closed a $5.5M Series A financing. Participants include vSpring Capital, Dow Venture Capital and Sun Mountain Capital.

Myoscience, Inc.: Series B $8.4M

Posted in I - Series B, Q - 2Q08, R - WEST, X - Aesthetics, X - Dermatology

Myoscience (Redwood City, CA) early-stage biotech focused on dermatology and aesthetic medicine closed a $8.4M Series B financing. Participants include Accuitive Medical Ventures, De Novo Ventures and Saratoga Ventures.

Tandem Diabetes Care, Inc.: Series B $13.1M

Posted in I - Series B, Q - 2Q08, R - WEST, X - Device (Diabetes)

Tandem Diabetes Care (San Diego, CA) focused on medical devices for diabetes closed a $13.1 Series B financing. Participants include Domain Associates, TPG Biotech and Second Technology Capital Investors.

AM-Pharma, BV: Series C $36M

Posted in I - Series C, Q - 2Q08, R - INTERNATIONAL, X - Autoimmune, X - Renal

AM-Pharma (Netherlands) biopharmaceutical company developing endogenous proteins and peptides to combat acute renal failure, ulcerative colitis and hospital acquired infections, closed a $36M Series C financing. Participants include Forbion Capital Partners and Inventages Venture Capital.

HyperMed, Inc.: Series B $4M

Posted in I - Series B, Q - 2Q08, R - NORTH EAST, X - Imaging

HyperMed (Burlington, MA) early-stage company focused on hyperspectral medical imaging, closed a $4M Series B financing. Participants include GBP Capital.

« Previous Entries Next Entries »

to top of page...